GS discussions leading biotech venture capital investors show a low enthusiasm for immuno-oncology (PD-1/PD-L1) &certain areas of cellular therapies such as CD19 CAR-Tswithin oncology, remains significant opportunity to better understand tumor microenviro

GS discussions leading biotech venture capital investors show a low enthusiasm for immuno-oncology (PD-1/PD-L1) &certain areas of cellular therapies such as CD19 CAR-Tswithin oncology, remains significant opportunity to better understand tumor microenvironment&tumor heterogeneity

More From BioPortfolio on "GS discussions leading biotech venture capital investors show a low enthusiasm for immuno-oncology (PD-1/PD-L1) &certain areas of cellular therapies such as CD19 CAR-Tswithin oncology, remains significant opportunity to better understand tumor microenviro"